TAKEDA PHARMACEUTIC-SP ADR (TAK) Stock Analyst Ratings
USA - NYSE:TAK - US8740602052 - ADR
14.015 USD
-0.04 (-0.32%)
ChartMill assigns a Buy % Consensus number of 74% to TAK. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 17.65. This target is 25.92% above the current price.
TAK was analyzed by 20 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about TAK.
In the previous month the buy percentage consensus was at a similar level.
TAK was analyzed by 20 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-05-16 | TD Cowen | Maintains | Outperform -> Outperform |
| 2023-04-04 | TD Cowen | Maintains | Outperform |
| 2023-03-16 | B of A Securities | Upgrade | Neutral -> Buy |
| 2022-07-19 | Cowen & Co. | Upgrade | Market Perform -> Outperform |
| 2021-10-07 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ
What is the price target for TAK stock?
20 analysts have analysed TAK and the average price target is 17.65 USD. This implies a price increase of 25.92% is expected in the next year compared to the current price of 14.015.
What is the consensus rating for TAKEDA PHARMACEUTIC-SP ADR (TAK) stock?
The consensus rating for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 74 / 100 . This indicates that analysts generally have a positive outlook on the stock.